Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4

Simple item page
dc.contributor.authorWeiner, Michael W.
dc.contributor.authorVeitch, Dallas P.
dc.contributor.authorMiller, Melanie J.
dc.contributor.authorAisen, Paul S.
dc.contributor.authorAlbala, Bruce
dc.contributor.authorBeckett, Laurel A.
dc.contributor.authorGreen, Robert C.
dc.contributor.authorHarvey, Danielle
dc.contributor.authorJack, Clifford R., Jr.
dc.contributor.authorJagust, William
dc.contributor.authorLandau, Susan M.
dc.contributor.authorMorris, John C.
dc.contributor.authorNosheny, Rachel
dc.contributor.authorOkonkwo, Ozioma C.
dc.contributor.authorPerrin, Richard J.
dc.contributor.authorPetersen, Ronald C.
dc.contributor.authorRivera-Mindt, Monica
dc.contributor.authorSaykin, Andrew J.
dc.contributor.authorShaw, Leslie M.
dc.contributor.authorToga, Arthur W.
dc.contributor.authorTosun, Duygu
dc.contributor.authorTrojanowski, John Q.
dc.contributor.authorAlzheimer's Disease Neuroimaging Initiative
dc.contributor.departmentRadiology and Imaging Sciences, School of Medicine
dc.date.accessioned2023-11-20T10:44:23Z
dc.date.available2023-11-20T10:44:23Z
dc.date.issued2023
dc.description.abstractIntroduction: The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. To improve generalizability, ADNI4 aims to enroll 50-60% of its new participants from underrepresented populations (URPs) using new biofluid and digital technologies. ADNI4 has received funding from the National Institute on Aging beginning September 2022. Methods: ADNI4 will recruit URPs using community-engaged approaches. An online portal will screen 20,000 participants, 4000 of whom (50-60% URPs) will be tested for plasma biomarkers and APOE. From this, 500 new participants will undergo in-clinic assessment joining 500 ADNI3 rollover participants. Remaining participants (∼3500) will undergo longitudinal plasma and digital cognitive testing. ADNI4 will add MRI sequences and new PET tracers. Project 1 will optimize biomarkers in AD clinical trials. Results and discussion: ADNI4 will improve generalizability of results, use remote digital and blood screening, and continue providing longitudinal clinical, biomarker, and autopsy data to investigators.
dc.eprint.versionFinal published version
dc.identifier.citationWeiner MW, Veitch DP, Miller MJ, et al. Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4. Alzheimers Dement. 2023;19(1):307-317. doi:10.1002/alz.12797
dc.identifier.urihttps://hdl.handle.net/1805/37144
dc.language.isoen_US
dc.publisherWiley
dc.relation.isversionof10.1002/alz.12797
dc.relation.journalAlzheimer's & Dementia
dc.rightsAttribution-NonCommercial 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourcePMC
dc.subjectAlzheimer's disease
dc.subjectAmyloid
dc.subjectCerebrovascular disease
dc.subjectDigital biomarkers
dc.subjectGeneralizability
dc.subjectMild cognitive impairment
dc.subjectPlasma biomarkers
dc.subjectTau
dc.subjectUnderrepresented populations
dc.titleIncreasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ALZ-19-307.pdf
Size:
885.12 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Radiology and Imaging Sciences Works